Siddharth Reddy, MD
Interventional Cardiology · Columbus, MSNPI 1760800338
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.3%), food and beverage and education — rather than concentrated in one kind of arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 23.5%.
Across 234 payments — averaging $85.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$5K
- Boston Scientific$4K
- Abiomed$4K
- Medtronic$3K
- Bard Peripheral Vascular, Inc.$1K
- Abbott$532
- plus $3K from 22 others
What the payments were for
- Consulting fees$1101%
- Travel & lodging$11,09655%
- Food & beverage$8,27041%
- Education$5213%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 14 | $4,727 |
| Boston Scientific | 35 | $3,626 |
| Abiomed | 44 | $3,555 |
| Medtronic(2 entities) | 30 | $2,985 |
| Bard Peripheral Vascular, Inc. | 11 | $1,477 |
| Abbott | 10 | $532 |
| Edwards Lifesciences | 6 | $499 |
| Inari Medical, Inc. | 4 | $349 |
| AstraZeneca | 11 | $313 |
| Amgen | 6 | $296 |
| Cardiovascular Systems Inc. | 6 | $235 |
| Biotronik Inc. | 3 | $228 |
| Novartis | 12 | $221 |
| E.r. Squibb & Sons, L.L.C. | 8 | $210 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $173 |
| Philips North America LLC | 4 | $152 |
| Angiodynamics, Inc. | 6 | $121 |
| Johnson & Johnson | 4 | $81 |
| Chiesi USA, Inc. | 1 | $75 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Heartflow, Inc. | 2 | $33 |
| Pfizer | 2 | $30 |
| Boehringer Ingelheim | 2 | $27 |
| W. L. Gore & Associates, Inc. | 1 | $21 |
| Lantheus Medical Imaging, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Merck | 1 | $17 |
| Lifenet Health | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$4,419
- Impella$2,846
- VENOVO$1,220
- Resolute$1,183
- TurboHawk$811
- Repatha$225
- Ensite Cardiac Mapping System$223
- FLOWTRIEVER CATHETER, S$202
- Edwards SAPIEN 3 Transcatheter Heart Valve$154
- Penumbra System$146
- AMVIA EDGE$141
- BioMonitor$141
- PAMIRA$141
- Diamondback Coronary$137
- CoreValve Evolut$126
- Watchman$116
- Stellarex Short$109
- CAMZYOS$106
- BRILINTA$106
- MitraClip$105
How this compares
$20,072 in reported general payments places this provider in the 75th percentile of 65 interventional cardiology providers in Mississippi.
See all interventional cardiology providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 198 | $139,906 |
| FarxigaDapagliflozin Propanediol | 110 | $102,949 |
| JardianceEmpagliflozin | 105 | $88,048 |
| EntrestoSacubitril/Valsartan | 81 | $75,293 |
| XareltoRivaroxaban | 82 | $65,297 |
| BrilintaTicagrelor | 83 | $47,152 |
| Repatha SureclickEvolocumab | 17 | $9,358 |
| Ranolazine ErRanolazine | 47 | $3,174 |
| Metoprolol Succinate | 286 | $2,629 |
| Valsartan | 121 | $2,553 |
| ClopidogrelClopidogrel Bisulfate | 179 | $1,871 |
| Atorvastatin Calcium | 267 | $1,656 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 109 | $1,089 |
| Furosemide | 243 | $924 |
| Carvedilol | 192 | $907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $313 | $150,101193 claims |
| PfizerEliquis | $30 | $139,906198 claims |
| Boehringer IngelheimJardiance | $27 | $88,048105 claims |
| NovartisEntresto | $221 | $75,29381 claims |
| Johnson & JohnsonXarelto | $81 | $65,29782 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 65 interventional cardiology providers in Mississippi.
Other interventional cardiology in Columbus
- John KingColumbus$74K
- John WinscottJackson$482K
- William CrowderJackson$331K
- Foluso FakoredeCleveland$298K
- James BennettJackson$160K
- Abdul BahroFlowood$132K
- Brett BennettJackson$126K
- Michael CunninghamBiloxi$45K
- Alejandro Lemor FerrandJackson$37K
- David YoungJackson$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.